MarketBeat.com – MarketBeat
Biotech stocks are often among the market’s most volatile, and Harpoon Therapeutics Inc. (NASDAQ: HARP) offers a perfect example of that.
The stock rocketed to an eight-month high Monday, advancing as much as 191% intraday before settling down to a gain of 22.61%. Shares closed at $1.41 Monday, up $0.26. Tuesday, the stock closed lower after gapping down at the open.
Monday’s huge upside action followed the company’s release of updated interim results for its myeloma drug that’s in Phase 1 clinical trials. The treatment is currently known as HPN217.
According to Harpoon’s news release, “The interim results, as of the data cut-off
→ Continue reading at Entrepreneur